Table 3.

Risk Factors for Mortality by Day 28 and Day 90 in Solid Organ Transplant Recipients Hospitalized for Coronavirus Disease 2019, Univariable Cox Proportional Hazards (N = 1117)

Covariate	Mortality by Day 28	Mortality by Day 90
	Hazard Ratio (95% Confidence Interval), P Value
Men	1.0 (.76–1.4), .91	1.2 (.9–1.6), .12
Age >65 years	2.1 (1.6–2.7), <.001	2.0 (1.6–2.6), <.001
Transplant within 2 years	0.76 (.55–1.0), .09	1.0 (.7–1.3), .81
Lung transplant (vs nonlung)	1.5 (1.0–2.2), .047	1.4 (1.0–1.9), .10
Comorbidities
Hypertension	1.3 (.9–1.9), .14	1.4 (1.0–1.9), .04
Diabetes mellitus	1.6 (1.2–2.2), .01	1.6 (1.3–2.1), <.001
Body mass index ≥30 kg/m2	1.5 (1.1–2.0), .01	1.3 (1.0–1.7), .06
Chronic kidney disease/end stage renal disease	1.3 (.98–1.8), .06	1.2 (.9–1.5), .24
Heart failure	2.8 (1.8–4.2), <.001	2.5 (1.7–3.6), <.001
Chronic lung disease	3.4 (2.3–4.9), <.001	2.9 (2.0–4.2), <.001
Baseline immunosuppression
Any CNI	1.1 (.6–1.8), .76	1.0 (.65–1.6), .96
Any antimetabolite	0.87(.6–1.2), .40	0.9 (.7–1.2), .56
Any corticosteroid	1.1 (.8–1.5), .58	1.1 (.8–1.4), .64
CNI, ant-metabolite, steroids	0.98 (.7–1.3), .87	1.0 (.8–1.2), .75
Any mammalian target of rapamycin inhibitor	0.3 (.1–.9), .03	0.4 (.2–.9), .03
Recent intensive immunosuppression	0.5 (.2–1.1), .09	0.9 (.5–1.5), .65
Time period of diagnosis
Late 2020 (on or after 20 June 2020)	0.7 (.5–.9), .01	0.9 (.7–1.1), .29
Markers of illness severity at presentation
Abnormal chest imaging	3.5 (1.9–6.4), <.001	3.4 (2.0–5.8), <.001
Lymphopenia (absolute lymphocyte count <0.5 × 109/L)	1.8 (1.3–2.4), <.001	1.8 (1.4–2.4), <.001

Abbreviation: CNI, calcineurin inhibitor.

Statistically significant values (P ≤ .05) are shown in bold.